Internal Medicine

Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.

Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.

The implant was linked to visual acuity improvements at final follow-up visit.

Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.

Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.

Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

The UCLA expert discusses the lengthy virtual agenda of this year's meeting, as well as his own session recommendations and key discussions.

These findings corroborate similar conclusions presented last year at ARVO.

Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The twice-daily oral agent is indicated for patients ≥3 years of age

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.

The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.

A cohort analysis of African American patients finds an association between 1-year ozone concentrations and diagnosed incident diabetes at clinical visit.

The nasal spray can be administered by anyone regardless of medical training.

Agency requests additional analyses on the novel mechanism of action on the serum phosphorus treatment for chronic kidney disease patients on dialysis.

Marla Dubinsky, MD, discusses what needs to be done to improve care for children with ulcerative colitis.